Patients The NHS risk crisis: The failure of risk in a complex health... *Disclaimer: The views and opinions expressed here are the author’s own and do not necessarily reflect those of pharmaphorum or its editorial staff.
News After setback, Rhythm gets good news on Imcivree from FDA Rhythm Pharma has secured the first approval in the US for a drug to treat hypothalamic obesity.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.